摘要Objective:To systematically evaluate the efficacy and safety of Compound Stomachache Capsule(复方胃痛胶囊)in the treatment of digestive ulcer and inflammation Helicobacter pylori-Peptic Ulcer(Hp-PU)caused by Helicobacter pylori(Hp).Methods:Randomized controlled trials(RCTs)of Compound Stomachache Capsule(复方胃痛胶囊)in the treatment of Hp-PU were screened out by searching CNKI,VIP,Wanfang,China Biomedical Literature Service System,Cochrane Library,PubMed,EMbase,Web of Science and ClinicalTrials.gov.Meta-analysis was performed with RevMan 5.4 software.Results:Three RCTs were included,including 331 patients of 166 patients in the experimental group(Compound Stomachache Capsule(复方胃痛胶囊)+conventional western medicine treatment)and 165 patients in the control group(conventional western medicine treatment).Meta-analysis data showed that Hp eradication rate(RR=1.10,95%CI[1.01-1.19],P=0.03)was significantly higher in the experimental group than in the control group.The experimental group was superior to the control group in improving clinical symptoms(RR=1.59,95%CI[1.22-2.06],P=0.0006).Conclusion:According to the current evidence,the Compound Stomachache Capsule(复方胃痛胶囊)combined with conventional Western medicine treatment can improve the Hp eradication rate of Hp-PU,relieve symptoms,and do not increase the incidence of adverse reactions.However,the number of included studies is small and the sample size is small,so its effectiveness and safety need further verification.